You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Spectroscopic presciption verification system

    SBC: CENTICE CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Prescription dispensing errors at a pharmacy are a problem on a national level, at a rate of about 4 errors per day in a pharmacy filling 250 prescriptions daily. This translates to a gigantic amount of 51 million prescription errors per year with about 3 billion prescriptions being filled. There are as many as 7,000 deaths reported annually in the United State ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Cell therapy of diabetes using broad spectrum multipotent stem cells

    SBC: PLUREON CORP.            Topic: N/A

    DESCRIPTION (provided by applicant): Transplantation of insulin-producing cells in many diabetes patients potentially would restore normal glucose homeostasis and prevent the severe long-term complications of the disease. However, the scarcity of donated pancreata currently limits transplantation of the whole organ or of isolated pancreatic islets to a tiny fraction of those patients who might ben ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Cell therapy of diabetes using broad spectrum multipotent stem cells

    SBC: PLUREON CORP.            Topic: N/A

    DESCRIPTION (provided by applicant): Transplantation of insulin-producing cells in many diabetes patients potentially would restore normal glucose homeostasis and prevent the severe long-term complications of the disease. However, the scarcity of donated pancreata currently limits transplantation of the whole organ or of isolated pancreatic islets to a tiny fraction of those patients who might ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Treatment in a Bioterrorism Model of Pneumonic Plague Targets A1 ARs

    SBC: ENDACEA, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Yersinia pestis (Y. pestis), the causative agent of plague, is a Gram-negative bacillus that is classified as a Category A pathogen by the Centers for Disease Control and a logical choice as a biological weapon. It has the potential to generate mass casualties and initiate a global epidemic of pneumonic plague. A major virulence factor for Y. pestis is endotoxi ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Novel treatment of posttraumatic stress disorder

    SBC: ANAGIN            Topic: 101

    DESCRIPTION provided by applicant The present application andquot Novel Treatment for Posttraumatic Stress Disorderandquot addresses the critical need for efficacious treatments for posttraumatic stress disorder PTSD A key neural signaling cascade activated by a trauma experience is initiated by the excitatory neurotransmitter glutamate Activation of the NMDA receptor a glutamate receptor ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas

    SBC: TYMORA ANALYTICAL OPERATIONS LLC            Topic: 300

    DESCRIPTION provided by applicant Mass spectrometry based proteomics is an emerging technology that has seen possible applications everywhere The technique can potentially use one drop of our blood to reveal onset and progress of diseases Current Randamp D using plasma serum proteome sample sets however is severely limited by the high complexity and dynamic range of protein concentrations ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Broadly Inhibitory MAbs Targeting Hepatitis C Virus Receptors

    SBC: PROGENICS PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 170 million people worldwide are infected with the hepatitis C virus (HCV) with another 3 to 4 million new infections each year. Chronically infected persons are at risk of developing severe and potentially life-threatening liver disease, including cirrhosis and hepatocellular carcinoma. There is currently no vaccine against HCV, and the available ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Developement of an alphavirus vaccine for melanoma

    SBC: PROGENICS PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Melanoma will strike an estimated 59,000 individuals and cause 7,700 deaths in the United States in 2005, and its incidence is rising faster than that of all other cancers except lung cancer. While primary tumors can be excised surgically, approximately half of all patients develop metastatic disease for which there are few treatment options. Thus, there is an ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government